Stevenage 75th anniversary magazine | biz4Biz - Magazine - Page 62
CGT Catapult
Innovative therapies require innovative
approaches. To accelerate getting these
therapies to patients, the CGT Catapult
established a unique model that has
attracted numerous national and
international cutting-edge companies
to Stevenage. Collaborating companies
benefit from the CGT Catapult’s
infrastructure and expertise to establish
technical manufacturing processes,
whilst helping to develop new
frameworks and processes to address
industry barriers together.
CLICK HERE FOR MORE INFO
Since 2018, the UK has seen £2.2 billion
invested into the cell and gene therapy
sector, including £1 billion raised by
companies collaborating with the CGT
Catapult Stevenage Manufacturing
Innovation Centre. This investment is
reflected in a 150% increase in the UK’s
cell and gene therapy manufacturing
space, and a significant increase in the
number of jobs in the cell and gene
therapy industry, from 1,500 to over
7,000. The future opportunities for
Stevenage are huge.
The CGT Catapult Manufacturing
Innovation Centre forms part of the
wider Stevenage Advanced Therapies
Campus which in 2020 was named a
High Potential Opportunity (HPO)
62
area by the Department for International
Trade (DIT), thus representing an
international hub of ground-breaking
research and development.
The future of Stevenage as centre of
the third largest cell and gene therapy
cluster globally
The attractiveness of Stevenage for the
cell and gene therapy industry continues
to grow, in part, thanks to the pioneering
work by the CGT Catapult and to the
continuous investment by the UK
Government, local government and
others.
Further backing and grant funding
also from the Hertfordshire Local
Enterprise Partnership is enabling the
CGT Catapult to develop additional
industry capabilities locally. Working
in collaboration with industry, CGT
Catapult is developing state-of-theart analytical technologies and skills
training laboratories that utilise virtual
and enhanced reality technology. By
benefitting from these, people can start
on a range of cell and gene therapy
career paths with local, national and
international companies.
CLICK HERE FOR VIDEO
CLICK HERE FOR CASE STUDY
CLICK HERE FOR VIDEO
w w w. b i z 4 b i z . o r g
In a recent report, the UK continues
to demonstrate that it is a leading
place of choice to set up cell and gene
therapy activities, with 29% of European
ATMP companies currently operating
in the UK. The advancements that are
being carried out by the CGT Catapult
and throughout the town are what
makes Stevenage an integral part of
driving innovation, both in the UK
and internationally, and more broadly
helping to bring these revolutionary
treatments to patients.
Having already made significant strides
for the UK and cell and the gene therapy
industry, the CGT Catapult believes that
Stevenage and the cluster around the
town will continue to play a significant
role in this growth as companies
continue to focus on bringing groundbreaking therapeutics to patients around
the world, using the invaluable expertise
established in Stevenage. This field is
predicted to see significant growth in the
coming years fuelled by the creation of
diverse, highly skilled jobs at all levels.
If you are interested in learning
more about the Cell and Gene
Therapy Catapult, or any of the
opportunities it offers, please contact
info@ct.catapult.org.uk